雾化黏菌素作为替代策略治疗ICU内CR-GNB所致医院获得性肺炎的作用:一项回顾性队列研究
这项回顾性队列研究纳入ICU内由黏菌素敏感CR-GNB所致医院获得性肺炎且未接受静脉黏菌素的患者,按是否联合其他静脉抗生素使用替代性雾化黏菌素分为两组,比较原始队列与倾向评分匹配队列的临床应答和死亡率。共343例使用与214例未使用替代性雾化黏菌素。PS匹配队列中,雾化黏菌素组第7天(22.6% vs 42.6%,p=0.001)、第14天(27.0% vs 42.6%,p=0.013)、第28天(27.8% vs 41.7%,p=0.027)临床失败率显著更低;多因素分析中雾化黏菌素与较低的第14天临床失败独立相关(原始队列aOR 0.45,95%CI 0.30-0.67;PS匹配队列aOR 0.48,95%CI 0.27-0.87)。高剂量(>6 MIU/天)与低剂量(≤6 MIU/天)雾化黏菌素在PS匹配队列中的临床失败率和死亡率无差异。作者结论认为,在黏菌素敏感CR-GNB所致医院获得性肺炎的ICU患者中,替代性雾化黏菌素与更好的临床结局相关。
要点
- PS匹配队列中,雾化黏菌素组第7天临床失败率22.6% vs 未使用组42.6%(p=0.001)。
- PS匹配队列中,雾化黏菌素组第14天临床失败率27.0% vs 未使用组42.6%(p=0.013)。
- PS匹配队列中,雾化黏菌素组第28天临床失败率27.8% vs 未使用组41.7%(p=0.027)。
- 多因素分析:雾化黏菌素与较低第14天临床失败独立相关,原始队列aOR 0.45(95%CI 0.30-0.67),PS匹配队列aOR 0.48(95%CI 0.27-0.87)。
- PS匹配队列中,高剂量(>6 MIU/天)与低剂量(≤6 MIU/天)雾化黏菌素的临床失败率和死亡率无差异。
适用人群与场景
- ICU内由黏菌素敏感CR-GNB所致医院获得性肺炎、且未接受静脉黏菌素治疗的患者。
处置流程与药物剂量
- 替代性雾化黏菌素作为其他静脉抗生素的联合策略使用;高剂量定义为>6 MIU/天,低剂量定义为≤6 MIU/天。
研究设计与关键结果
- 回顾性队列研究,共纳入557例患者,其中使用替代性雾化黏菌素343例、未使用214例。
- PS匹配队列中,第7天临床失败率雾化黏菌素组22.6% vs 未使用组42.6%(p=0.001);第14天27.0% vs 42.6%(p=0.013);第28天27.8% vs 41.7%(p=0.027)。
- 多因素分析中,雾化黏菌素与较低的第14天临床失败独立相关:原始队列aOR 0.45(95%CI 0.30-0.67),PS匹配队列aOR 0.48(95%CI 0.27-0.87)。
- PS匹配队列中,高剂量(>6 MIU/天)与低剂量(≤6 MIU/天)雾化黏菌素组间的临床失败率和死亡率无差异。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在ICU内黏菌素敏感CR-GNB所致医院获得性肺炎且未静脉使用黏菌素的患者中,替代性雾化黏菌素与更好的临床结局相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Adverse reactions, especially nephrotoxicity, are great concerns of intravenous colistin treatment. The role of substitutive nebulized colistin in treating nosocomial pneumonia caused by carbapenem-resistant Gram-negative bacterial (CR-GNB) in critically ill patients remains unknown.
METHODS: This retrospective study enrolled patients with nosocomial pneumonia caused by colistin-susceptible CRGNB in the intensive care unit (ICU) without intravenous colistin treatment. Patients were categorized based on whether substitutive nebulized colistin was used alongside other intravenous antibiotics. Clinical responses and mortality rates were compared between the two groups in the original and propensity score (PS)-matched cohorts. This study aimed to investigate the clinical effectiveness of substitutive nebulized colistin in treatment outcomes of nosocomial pneumonia caused by CR-GNB. The impact of dosing strategy of nebulized colistin was also explored.
RESULTS: In total, 343 and 214 patients with and without substitutive nebulized colistin, respectively, were enrolled for analysis. In the PS-matched cohort, clinical failure rates on day 7 (22.6 vs. 42.6%, p = 0.001), day 14 (27.0 vs. 42.6%, p = 0.013), and day 28 (27.8 vs. 41.7%, p = 0.027) were significantly lower in patients with nebulized colistin. In multivariate analysis, nebulized colistin was an independent factor associated with lower day 14 clinical failure (Original cohort: adjusted odds ratio (aOR) 0.45, 95% confidence interval (CI) 0.30-0.67; PS-matched cohort: aOR 0.48, 95% CI 0.27-0.87). There were no differences in clinical failure rate and mortality rate between patients receiving high (> 6 MIU/day) and low (≤ 6 MIU/day) dose nebulized colistin in the PS-matched cohort.
CONCLUSIONS: In ICU-admitted patients with nosocomial pneumonia caused by colistin-susceptible CRGNB, substitutive nebulized colistin was associated with better clinical outcomes.
参考来源
- Feng JY, Huang JR, Lee CC, et al. Role of nebulized colistin as a substitutive strategy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective cohort study. Ann Intensive Care. 2023. PMID: 36609725. doi:10.1186/s13613-022-01088-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。